When traditional oral analgesics no longer control pain, some physicians are turning to alternative drug delivery methods that provide pain relief while avoiding systemic adverse effects.
This study provides normative values for the bilateral lumbar and sacral-anorectal MEPs in healthy subject with no age or gender influence on rectal or anal MEP latency.
BoNT-A showed significant improvements in the frequency and severity of photophobia and eye discomfort.
There is limited evidence supporting the efficacy of cannabis for refractory chronic pain, including chronic neuropathic pain.
The FDA has granted Fast Track designation to ANX005 for the treatment of Guillain-Barré Syndrome, an autoimmune disease that can lead to widespread peripheral nerve damage and paralysis.
Investigators analyzed whether high LDL-C causally relates to risk for retinopathy, neuropathy, chronic kidney disease, and peripheral artery disease in the general population.
CNTX-6016, a highly-selective cannabinoid receptor type 2 agonist, was found to provide adequate analgesia in preclinical models of neuropathic pain.
Recognition of the wide phenotype spectrum in immune checkpoint inhibitor-related neuropathy and prompt management with corticosteroids may lead to favorable outcomes.
Computed tomography-guided pulsed radiofrequency therapy may offer pain relief, improve quality of life, and reduce medication use in patients with trigeminal postherpetic neuralgia.
Hereditary transthyretin-related amyloidosis (hATTR) with polyneuropathy is a rare, progressive and fatal disease that has been challenging for neurologists to diagnose and manage, until now. Advances in genetic testing have yielded the development of a new generation of more efficient screenings that make early, accurate, and rapid diagnosis more accessible.